Full Text
EE498 Cost-per-Responder Analysis of Bimekizumab Vs Other Licensed Anti-Interleukin Therapies in Psoriatic Arthritis from a UK Perspective

Abstract

Authors

N. Bithal T. Rehman C. McCabe F. Obam D. Willems

Back to Volume 26, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×